NEO NeoGenomics, Inc. - Common Stock
NASDAQ · Health Care · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Tem 28, 2026
$18,47
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$7,0752 haftanın en düşüğü
$20,0552 haftanın en yükseği
Piyasa Değeri (MRQ)
$2.36B
P/E
-77.9
Gelir
$727M
rozetleriniz
52 Haftlık Aralık
$7–$20
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$20
P/E
-77.9
ROE
-12.8%
Net Kâr Marjı
-6.8%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
NEO Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$18.47
Piyasa Değeri (MRQ)
$2.36B
P/E
-77.9
Gelir
$727M
ROE
-12.8%
D/E Borç/Özsermaye (MRQ)
0.5
52 Haftlık Aralık
$7–$20
NEO Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
NeoGenomics, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.
## History
NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH.
In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.
In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc., a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.
In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland.
In September 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealth Care
endüstriHealth Care
çalışanlar2.500
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$727M2016-12-31 → 2025-12-31
Serbest Nakit Akışı$-22M2017-12-31 → 2025-12-31
Net kar marjı-6.8%2019-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | NEO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -77.95Y ort. ≈-73.2 | ≈-73.2 | · | · | |
| F/S (TTM) | 3.15Y ort. ≈3.8 | ≈3.8 | 1.1 | Aşırı değerli | |
| F/D (MRQ) | 3.05Y ort. ≈2.2 | ≈2.2 | 2.4 | Adil değer | |
| EV / EBITDA | -22.2 | · | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -321.25Y ort. ≈-50.3 | ≈-50.3 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 107.25Y ort. ≈-125.0 | ≈-125.0 | 13.5 | Aşırı değerli | |
| EV / Revenue (EV / Gelir) | 3.5 | · | · | · | |
| EV / FCF | -118.3 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 4.65Y ort. ≈40.2 | ≈40.2 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | NEO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Brüt Kar Marjı (TTM) | 43.9%5Y ort. ≈40.8% | ≈40.8% | 32.6% | En üst düzey | |
| Faaliyet Kâr Marjı (TTM) | -8.9%5Y ort. ≈-20.7% | ≈-20.7% | 4.0% | Zayıf | |
| EBITDA Margin (FAVÖK Marjı) | -15.9%5Y ort. ≈-20.7% | ≈-20.7% | 4.5% | Zayıf | |
| Vergi Öncesi Kar Marjı (TTM) | -7.1%5Y ort. ≈-15.6% | ≈-15.6% | 3.3% | Zayıf | |
| Net Kâr Marjı (TTM) | -6.8%5Y ort. ≈-14.3% | ≈-14.3% | 2.4% | Zayıf | |
| ROA | -7.2%5Y ort. ≈-5.1% | ≈-5.1% | 1.8% | Zayıf | |
| ROE | -12.8%5Y ort. ≈-9.2% | ≈-9.2% | 3.3% | Zayıf | |
| ROIC | -9.6%5Y ort. ≈-9.3% | ≈-9.3% | 5.0% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | NEO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.5 | · | 0.3 | Yüksek borç | |
| Cari Oran (MRQ) | 3.65Y ort. ≈5.4 | ≈5.4 | 1.5 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 3.65Y ort. ≈3.9 | ≈3.9 | 1.2 | Güçlü likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.5 | · | 0.4 | Yüksek borç |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | NEO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 10.1%5Y ort. ≈10.4% | ≈10.4% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 12.6%5Y ort. ≈11.2% | ≈11.2% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 10.3% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | NEO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.55Y ort. ≈0.4 | ≈0.4 | 1.6 | Zayıf | |
| Inventory Turnover (Stok Devir Hızı) | 14.95Y ort. ≈13.7 | ≈13.7 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 4.75Y ort. ≈4.6 | ≈4.6 | 8.4 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$290.9K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
55.4%
Sonraki Rapor
Eki 26, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Tem 27, 2026 | $0.05 | $0.03 | 51.1% |
| 31 Mart 2026 | $0.01 | $0.01 | — | |
| 31 Aralık 2025 | $0.06 | $0.04 | 53.5% | |
| 30 Eylül 2025 | $0.03 | $0.02 | 40.8% | |
| 30 Haziran 2025 | $0.03 | $0.02 | 31.6% | |
| 31 Mart 2025 | $0.00 | $-0.01 | 100.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M | $5M | $5M | |
| Cost of Revenue | $413M | $370M | $347M | $322M | $297M | $259M | $212M | $149M | $138M | $134M | $56M | $46M | |
| Gross Profit | $314M | $290M | $245M | $188M | $187M | $186M | $197M | $127M | $102M | $98M | $44M | $41M | |
| R&D Expense | $37M | $31M | $27M | $30M | $22M | $8M | $8M | $3M | $4M | $5M | $4M | $3M | |
| SG&A Expense | $273M | $260M | $243M | $243M | $221M | $144M | $128M | $85M | $70M | $64M | $34M | $24M | |
| Operating Expenses | $430M | $382M | $352M | $346M | $306M | $200M | $184M | $117M | $99M | $96M | $49M | $38M | |
| Operating Income | $-116M | $-92M | $-108M | $-158M | $-119M | $-14M | $13M | $10M | $3M | $2M | $-6M | $2M | |
| Interest Expense | · | · | $7M | $8M | $8M | $7M | $4M | $6M | $6M | · | $854.0K | $985.0K | |
| Interest Income | $9M | $18M | $17M | $6M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $296.0K | $-379.0K | $644.0K | $-213.0K | $-499.0K | $8M | $-5M | $14.0K | $-12.0K | $0 | $2M | $56.0K | |
| Pretax Income | $-110M | $-81M | $-97M | $-159M | $-15M | $-14M | $4M | $4M | $-3M | $-8M | $-4M | $1M | |
| Income Tax | $-2M | $-2M | $-9M | $-15M | $-7M | $-18M | $-4M | $1M | $-2M | $-2M | $-2M | $157.0K | |
| Net Income | $-108M | $-79M | $-88M | $-144M | $-8M | $4M | $8M | $3M | $-396.0K | $-6M | $-3M | $1M | |
| EPS (Basic) | · | · | · | · | · | · | · | · | · | · | $-0.04 | $0.02 | |
| EPS (Diluted) | · | · | · | · | · | · | · | · | · | · | $-0.04 | $0.02 | |
| Shares (Basic) | 128,101,000 | 126,658,000 | 125,502,000 | 124,217,000 | 119,962,000 | 108,579,000 | 100,470,000 | 85,618,000 | 79,426,000 | 77,542,000 | 60,526,000 | 53,483,000 | |
| Shares (Diluted) | 128,101,000 | 126,658,000 | 125,502,000 | 124,217,000 | 119,962,000 | 111,794,000 | 103,615,000 | 91,568,000 | 79,426,000 | 77,542,000 | 60,526,000 | 56,016,000 | |
| EBITDA | $-116M | $-92M | $-108M | $-158M | $-119M | $-14M | $13M | · | $2M | · | $-6M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $160M | $367M | $342M | $263M | $317M | $229M | $173M | $10M | $13M | $13M | $23M | $34M | |
| Receivables | $159M | $151M | $131M | $120M | $112M | $107M | $94M | $77M | $60M | $56M | $49M | $20M | |
| Inventory | $29M | $27M | $24M | $24M | $23M | $30M | $14M | $9M | $7M | $6M | $5M | $3M | |
| Prepaid Expense | $21M | $20M | $18M | $15M | $12M | $12M | $6M | $8M | $5M | $5M | $5M | $1M | |
| Other Current Assets | $7M | $12M | $8M | $8M | $8M | $5M | $3M | $561.0K | $1M | · | · | · | |
| Current Assets | $376M | $596M | $597M | $605M | $682M | $449M | $291M | $104M | $86M | $79M | $82M | $59M | |
| PP&E (Net) | $85M | $94M | $92M | $102M | $109M | $86M | $64M | $61M | $37M | $34M | $35M | $15M | |
| PP&E (Gross) | $294M | $284M | $250M | $234M | $219M | $179M | $133M | $111M | $77M | $61M | $61M | $35M | |
| Accum. Depreciation | $209M | $190M | $158M | $132M | $110M | $93M | $69M | $50M | $41M | $27M | $27M | $20M | |
| Goodwill | $524M | $523M | $523M | $523M | $527M | $211M | $199M | $198M | $147M | $147M | $147M | $3M | |
| Intangibles | $287M | $340M | $373M | $408M | $442M | $121M | $127M | $140M | $74M | $77M | $88M | $4M | |
| Other Non-current Assets | $9M | $6M | $5M | $5M | $7M | $5M | $3M | $3M | $891.0K | $174.0K | $129.0K | $141.0K | |
| Total Assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988M | $710M | $505M | $344M | $337M | $351M | $81M | |
| Accounts Payable | $23M | $22M | $20M | $21M | $18M | $25M | $20M | $18M | $10M | $17M | $12M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Liabilities | $88M | $301M | $96M | $90M | $87M | $73M | $64M | $61M | $36M | $38M | $40M | $15M | |
| Capital Leases | $63M | $61M | $68M | $69M | $72M | $42M | $24M | $5M | $5M | $5M | $5M | $5M | |
| Deferred Tax | $18M | $22M | $24M | $35M | $55M | $5M | $16M | $22M | $7M | · | $16M | $821.0K | |
| Other Non-current Liabilities | $12M | $12M | $13M | $13M | $14M | $4M | $4M | $3M | $283.0K | · | · | · | |
| Total Liabilities | $523M | $736M | $740M | $742M | $762M | $294M | $202M | $185M | $140M | $151M | $113M | $21M | |
| Long-term Debt | $342M | $541M | $538M | · | · | · | · | $102M | $97M | $98M | $55M | · | |
| Total Debt | $342M | $541M | · | · | · | $0 | · | · | $95M | · | $53M | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | $60.0K | |
| Retained Earnings | $-434M | $-326M | $-247M | $-159M | $-15M | $-7M | $-11M | $-19M | $-58M | $-52M | $-22M | $-19M | |
| Treasury Stock | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $4.0K | $-206.0K | $-2M | $-4M | $-638.0K | $10.0K | $-2M | $-579.0K | $274.0K | · | · | · | |
| Stockholders' Equity | $837M | $902M | $942M | $998M | $1.11B | $694M | $507M | $320M | $172M | $162M | $209M | $60M | |
| Liabilities + Equity | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988M | $710M | $505M | $344M | $337M | $351M | $81M | |
| Shares Outstanding | 128,989,152 | 128,145,333 | 127,369,142 | 126,913,992 | 124,107,500 | 112,075,474 | 104,781,236 | 94,465,440 | 80,462,574 | 78,571,158 | 75,820,307 | 60,242,818 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $26M | $20M | $16M | $16M | $16M | $7M | $5M | |
| Stock-based Comp | $41M | $33M | $25M | $25M | $22M | $10M | $10M | $7M | $6M | $5M | $3M | $641.0K | |
| Deferred Tax | $-3M | $-3M | $-10M | $-15M | $-7M | $-18M | $-4M | $2M | $-2M | $-2M | $-2M | · | |
| Amort. of Intangibles | $32M | $33M | $35M | $34M | $23M | $10M | $10M | $6M | $7M | $7M | $412.0K | $295.0K | |
| Restructuring | $0 | $7M | $11M | $5M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $5M | $7M | $-2M | $-66M | $-27M | $1M | $23M | $45M | $18M | $21M | $6M | $9M | |
| CapEx | $27M | $41M | $29M | $31M | $64M | $29M | $20M | $14M | $14M | $8M | $2M | $4M | |
| Investing Cash Flow | $-12M | $13M | $77M | $517.0K | $-632M | $-159M | $-20M | $-140M | $-14M | · | · | · | |
| Stock Issued | $962.0K | $5M | $5M | $13M | $15M | $20M | $11M | $9M | $3M | · | · | $34M | |
| Net Stock Activity | $962.0K | $5M | $5M | $13M | $15M | $20M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-200M | $5M | $5M | $12M | $725M | $236M | $159M | $92M | $-4M | · | · | · | |
| Net Change in Cash | · | · | · | · | · | $78M | $163M | $-3M | $296.0K | $-11M | $-10M | $29M | |
| Taxes Paid | $515.0K | $207.0K | $175.0K | $180.0K | $148.0K | $246.0K | $319.0K | $-31.0K | $284.0K | $290.0K | · | · | |
| Free Cash Flow | $-22M | $-34M | $-31M | $-97M | $-91M | $-28M | $3M | · | $4M | · | $4M | · | |
| Levered FCF | · | · | $-37M | $-98M | $-94M | $-26M | $-5M | · | · | · | $4M | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | · | · | · | 875.1% | · | |
| Operating Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | · | · | · | -112.7% | · | |
| Net Margin | -14.8% | -11.9% | -14.9% | -28.3% | -1.7% | 0.94% | 2.0% | · | · | · | -50.7% | · | |
| Pretax Margin | -15.2% | -12.2% | -16.4% | -31.3% | -3.1% | -3.2% | 0.89% | · | · | · | -89.8% | · | |
| EBITDA Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | · | · | · | -112.7% | · | |
| ROA | -7.2% | -4.7% | -5.1% | -8.0% | -0.58% | 0.49% | 1.3% | · | -0.25% | · | -1.1% | · | |
| ROE | -12.8% | -8.7% | -9.3% | -14.3% | -0.74% | 0.61% | 1.6% | · | -0.50% | · | -1.9% | · | |
| ROIC | -9.6% | -6.2% | -10.4% | -14.3% | -5.9% | 0.60% | 5.6% | · | 0.21% | · | -1.2% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | 2.0 | 6.2 | 6.7 | 7.8 | 6.1 | 4.5 | · | 2.4 | · | 2.5 | · | |
| Quick Ratio | 3.6 | 1.7 | 4.9 | 4.3 | 4.9 | 4.6 | 4.2 | · | 2.1 | · | 1.8 | · | |
| Debt / Equity | 0.4 | 0.6 | · | · | · | 0.0 | · | · | 0.5 | · | 0.3 | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | · | · | · | · | · | 0.5 | · | 0.2 | · | |
| Interest Coverage | · | · | -15.6 | -104.7 | -23.4 | -2.0 | 3.5 | · | · | · | -6.6 | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 | 0.7 | · | · | · | 0.0 | · | |
| Inventory Turnover | 14.9 | 14.6 | 14.3 | 13.5 | 11.2 | 11.8 | 18.4 | · | 20.1 | · | 14.5 | · | |
| Receivables Turnover | 4.7 | 4.7 | 4.7 | 4.4 | 4.4 | 4.4 | 4.8 | · | · | · | 0.1 | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.53 | $7.08 | $7.42 | $8.04 | $9.89 | $6.63 | $5.37 | · | $2.15 | · | $2.76 | · | |
| Revenue / Share | $5.68 | $5.22 | $4.71 | $4.10 | $4.04 | $3.98 | $3.95 | · | · | · | $0.08 | · | |
| Cash Flow / Share | $0.04 | $0.06 | $-0.02 | $-0.53 | $-0.22 | $0.01 | $0.23 | · | $0.23 | · | $0.11 | · | |
| Cash / Share | $1.25 | $2.88 | $2.70 | $2.12 | $2.83 | $2.18 | $1.83 | · | $0.16 | · | $0.31 | · | |
| EPS (TTM) | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.04 | $0.02 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.1% | 11.7% | 16.1% | 5.2% | 9.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.6% | 10.9% | 10.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 10.3% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M | $5M | $5M | |
| Net Income TTM | $-108M | $-79M | $-88M | $-144M | $-8M | $4M | $8M | $3M | $-396.0K | $-6M | $-3M | $1M | |
| Market Cap | $1.51B | $2.10B | $2.05B | $1.15B | $3.82B | $5.64B | $2.76B | · | $713M | · | $597M | · | |
| Enterprise Value | $1.69B | $2.27B | · | · | · | $5.41B | · | · | $795M | · | $626M | · | |
| P/E | -49.0 | -68.7 | -67.4 | -38.5 | -142.2 | -224.3 | -121.9 | -52.5 | -36.9 | -35.7 | -196.8 | 208.5 | |
| P/S | 2.1 | 3.2 | 3.5 | 2.2 | 7.9 | 12.7 | 6.8 | · | 3.0 | · | 119.3 | · | |
| P/B | 1.8 | 2.3 | 2.2 | 1.1 | 3.5 | 8.1 | 5.4 | · | 4.1 | · | 2.8 | · | |
| P / Tangible Book | 58.7 | 52.6 | 45.0 | 17.1 | 27.5 | 15.6 | · | · | · | · | · | · | |
| P / Cash Flow | 288.1 | 298.9 | -1051.4 | -17.4 | -143.1 | 3864.0 | 118.2 | · | 39.5 | · | 93.3 | · | |
| P / FCF | -69.2 | -61.7 | -66.9 | -11.8 | -42.1 | -204.1 | 827.3 | · | 164.0 | · | 142.8 | · | |
| EV / EBITDA | -14.6 | -24.7 | · | · | · | -386.8 | · | · | 342.1 | · | -111.1 | · | |
| EV / FCF | -77.6 | -66.8 | · | · | · | -195.9 | · | · | 182.9 | · | 149.9 | · | |
| EV / Revenue | 2.3 | 3.4 | · | · | · | 12.2 | · | · | 3.3 | · | 125.2 | · | |
| Earnings Yield | -2.0% | -1.5% | -1.5% | -2.6% | -0.70% | -0.45% | -0.82% | -1.9% | -2.7% | -2.8% | -0.51% | 0.48% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $202M | $187M | $190M | $188M | $181M | $168M | $172M | $168M | $165M | $156M | $156M | $152M | $147M | $137M | $139M | $129M | |
| Cost of Revenue | $110M | $106M | $107M | $107M | $104M | $95M | $95M | $93M | $92M | $91M | $88M | $90M | $87M | $82M | $82M | $80M | |
| Gross Profit | $92M | $81M | $83M | $80M | $77M | $73M | $77M | $75M | $72M | $65M | $68M | $62M | $60M | $55M | $57M | $49M | |
| R&D Expense | $11M | $10M | $9M | $9M | $9M | $10M | $8M | $8M | $8M | $8M | $7M | $5M | $8M | $7M | $7M | $7M | |
| SG&A Expense | $64M | $66M | $64M | $70M | $72M | $68M | $64M | $67M | $63M | $66M | $60M | $61M | $60M | $62M | $55M | $64M | |
| Operating Expenses | $102M | $99M | $97M | $107M | $125M | $101M | $96M | $96M | $94M | $96M | $86M | $87M | $90M | $90M | $83M | $88M | |
| Operating Income | $-10M | $-18M | $-13M | $-27M | $-48M | $-28M | $-18M | $-21M | $-22M | $-31M | $-19M | $-24M | $-30M | $-35M | $-26M | $-40M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $2M | · | $-3M | $-3M | $2M | · | $139.0K | |
| Interest Income | $1M | $1M | $2M | $2M | $2M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | · | · | |
| Other Non-op | $-17.0K | $-12.0K | $84.0K | $-335.0K | $482.0K | $65.0K | $-431.0K | $317.0K | $-2.0K | $-263.0K | $124.0K | $-96.0K | $730.0K | $-114.0K | $-1.0K | $25.0K | |
| Pretax Income | $2M | $-18M | $-12M | $-26M | $-46M | $-26M | $-16M | $-18M | $-19M | $-28M | $-15M | $-21M | $-27M | $-34M | $-26M | $-40M | |
| Income Tax | $-412.0K | $-472.0K | $-3M | $740.0K | $-724.0K | $266.0K | $-804.0K | $-150.0K | $-375.0K | $-620.0K | $-960.0K | $-3M | $-2M | $-3M | $-3M | $-3M | |
| Net Income | $2M | $-17M | $-10M | $-27M | $-45M | $-26M | $-15M | $-18M | $-19M | $-27M | $-14M | $-19M | $-24M | $-31M | $-23M | $-37M | |
| Shares (Basic) | 129,628,000 | 129,166,000 | · | 128,415,000 | 127,949,000 | 127,376,000 | · | 126,953,000 | 126,405,000 | 126,111,000 | · | 125,687,000 | 125,356,000 | 125,026,000 | · | 124,425,000 | |
| Shares (Diluted) | 130,831,000 | 129,166,000 | · | 128,415,000 | 127,949,000 | 127,376,000 | · | 126,953,000 | 126,405,000 | 126,111,000 | · | 125,687,000 | 125,356,000 | 125,026,000 | · | 124,425,000 | |
| EBITDA | $-10M | $-18M | · | $-27M | $-48M | $-28M | · | $-21M | $-22M | $-31M | · | $-24M | $-30M | $-35M | · | $-40M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $146M | $146M | $160M | $164M | $155M | $346M | $367M | $362M | $355M | $332M | · | $306M | $289M | $276M | · | $266M | |
| Receivables | $175M | $167M | $159M | $155M | $153M | $151M | $151M | $151M | $147M | $140M | · | $133M | $125M | $119M | · | $112M | |
| Inventory | $27M | $30M | $29M | $28M | $34M | $30M | $27M | $24M | $23M | $20M | · | $24M | $25M | $24M | · | $24M | |
| Prepaid Expense | $24M | $24M | $21M | $22M | $23M | $23M | $20M | $18M | $17M | $19M | · | $19M | $17M | $16M | · | $17M | |
| Other Current Assets | $10M | $7M | $7M | $11M | $10M | $12M | $12M | $8M | $9M | $9M | · | $9M | $8M | $8M | · | $8M | |
| Current Assets | $381M | $374M | $376M | $382M | $393M | $574M | $596M | $590M | $584M | $574M | · | $587M | $585M | $585M | · | $603M | |
| PP&E (Net) | $81M | $84M | $85M | $85M | $85M | $90M | $94M | $93M | $92M | $88M | · | $95M | $100M | $103M | · | $107M | |
| PP&E (Gross) | · | · | $294M | · | · | · | $284M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $223M | $216M | $209M | $209M | $201M | $199M | $190M | $181M | $176M | $168M | · | $155M | $147M | $139M | · | $125M | |
| Goodwill | $524M | $524M | $524M | $524M | $524M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | · | $523M | |
| Intangibles | $271M | $279M | $287M | $294M | $302M | $331M | $340M | $348M | $356M | $365M | · | $382M | $391M | $399M | · | $417M | |
| Other Non-current Assets | $9M | $10M | $9M | $8M | $7M | $6M | $6M | $6M | $4M | $4M | · | $5M | $5M | $5M | · | $7M | |
| Total Assets | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | · | $1.68B | $1.70B | $1.71B | · | $1.76B | |
| Accounts Payable | $21M | $26M | $23M | $23M | $27M | $16M | $22M | $17M | $17M | $18M | · | $17M | $18M | $23M | · | $14M | |
| Current Liabilities | $106M | $85M | $88M | $98M | $100M | $280M | $301M | $296M | $290M | $77M | · | $93M | $95M | $87M | · | $85M | |
| Capital Leases | $65M | $61M | $63M | $64M | $67M | $60M | $61M | $62M | $63M | $65M | · | $62M | $65M | $67M | · | $70M | |
| Deferred Tax | $17M | $17M | $18M | $21M | $20M | $21M | $22M | $23M | $23M | $23M | · | $25M | $29M | $32M | · | $38M | |
| Other Non-current Liabilities | $862.0K | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $13M | · | $13M | $13M | $13M | · | $14M | |
| Total Liabilities | $567M | $518M | $523M | $536M | $540M | $713M | $736M | $733M | $727M | $717M | · | $731M | $739M | $735M | · | $743M | |
| Long-term Debt | · | · | $342M | · | · | · | $541M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $374M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-449M | $-451M | $-434M | $-424M | $-397M | $-352M | $-326M | $-310M | $-293M | $-274M | · | $-233M | $-214M | $-190M | · | $-136M | |
| Treasury Stock | $25M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $4.0K | $4.0K | $4.0K | $71.0K | $29.0K | $-56.0K | $-206.0K | $-643.0K | $-1M | $-1M | · | $-2M | $-3M | $-3M | · | $-5M | |
| Stockholders' Equity | $786M | $829M | $837M | $838M | $854M | $888M | $902M | $908M | $916M | $923M | $942M | $947M | $956M | $974M | $998M | $1.01B | |
| Liabilities + Equity | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | · | $1.68B | $1.70B | $1.71B | · | $1.76B | |
| Shares Outstanding | 127,917,946 | 129,653,642 | 128,145,333 | 128,885,101 | 128,681,713 | 128,356,327 | 128,145,333 | 128,061,944 | 127,851,113 | 127,434,786 | 127,369,142 | 127,261,476 | 127,144,418 | 127,200,491 | 126,913,992 | 126,562,037 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $8M | $10M | $8M | $10M | $12M | $11M | $8M | $0 | $9M | $8M | $7M | $0 | $6M | $5M | $5M | $4M | |
| Amort. of Intangibles | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | $9M | $9M | $9M | $9M | $8M | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $1M | $2M | $3M | $5M | · | $0 | |
| Operating Cash Flow | $20M | $-8M | $1M | $9M | $20M | $-25M | $10M | $9M | $14M | $-26M | $18M | $-5M | $-2M | $-13M | $-4M | $-16M | |
| CapEx | $8M | $5M | $8M | $8M | $6M | $4M | $12M | $11M | $13M | $6M | $7M | $4M | $7M | $10M | $5M | $8M | |
| Investing Cash Flow | $-8M | $-5M | $-6M | $-277.0K | $-9M | $4M | $-5M | $-4M | $7M | $15M | $17M | $21M | $15M | $24M | $-1M | $-4M | |
| Stock Issued | $2M | $-338.0K | $431.0K | $765.0K | $-1M | $949.0K | $687.0K | $1M | $2M | $816.0K | $1M | $2M | $93.0K | $1M | $2M | $3M | |
| Net Stock Activity | · | $-338.0K | · | · | · | $949.0K | · | · | · | $816.0K | · | · | · | $1M | · | · | |
| Financing Cash Flow | $-12M | $-338.0K | $431.0K | $765.0K | $-202M | $949.0K | $687.0K | $1M | $2M | $816.0K | $1M | $2M | $64.0K | $1M | $2M | $3M | |
| Net Change in Cash | · | · | · | $9M | · | · | · | $7M | $23M | $-11M | · | $17M | $13M | $12M | · | $-18M | |
| Taxes Paid | $711.0K | $0 | $57.0K | $0 | $458.0K | $0 | $-112.0K | $143.0K | $87.0K | $89.0K | $0 | $0 | $175.0K | $0 | $25.0K | $26.0K | |
| Free Cash Flow | · | $-13M | · | · | · | $-30M | · | · | · | $-32M | · | · | · | $-23M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-33M | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.6% | 43.3% | · | 42.8% | 42.6% | 43.6% | · | 44.6% | 44.1% | 41.9% | · | 41.0% | 40.8% | 40.0% | · | 38.0% | |
| Operating Margin | -4.9% | -9.8% | · | -14.4% | -26.3% | -16.6% | · | -12.6% | -13.3% | -19.6% | · | -15.9% | -20.3% | -25.6% | · | -30.7% | |
| Net Margin | 1.1% | -9.2% | · | -14.4% | -24.9% | -15.4% | · | -10.5% | -11.3% | -17.3% | · | -12.2% | -16.6% | -22.4% | · | -28.6% | |
| Pretax Margin | 0.91% | -9.4% | · | -14.1% | -25.3% | -15.3% | · | -10.6% | -11.6% | -17.7% | · | -14.1% | -18.1% | -24.6% | · | -30.8% | |
| EBITDA Margin | -4.9% | -9.8% | · | -14.4% | -26.3% | -16.6% | · | -12.6% | -13.3% | -19.6% | · | -15.9% | -20.3% | -25.6% | · | -30.7% | |
| ROA | 0.16% | -1.2% | · | -1.8% | -3.0% | -1.6% | · | -1.1% | -1.1% | -1.6% | · | -1.1% | -1.4% | -1.7% | · | -2.0% | |
| ROE | 0.27% | -2.0% | · | -3.1% | -5.1% | -2.9% | · | -1.9% | -2.0% | -2.9% | · | -1.9% | -2.4% | -3.0% | · | -3.4% | |
| ROIC | -1.0% | -2.1% | · | -3.3% | -5.5% | -3.2% | · | -2.3% | -2.4% | -3.2% | · | -2.2% | -2.9% | -3.3% | · | -3.6% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 4.4 | · | 3.9 | 3.9 | 2.1 | · | 2.0 | 2.0 | 7.5 | · | 6.3 | 6.2 | 6.8 | · | 7.1 | |
| Quick Ratio | 3.0 | 3.7 | · | 3.3 | 3.1 | 1.8 | · | 1.7 | 1.7 | 6.2 | · | 4.7 | 4.4 | 4.6 | · | 4.4 | |
| Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -18.1 | · | 8.5 | 11.8 | · | · | -284.2 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.6 | 3.6 | · | 4.1 | 3.6 | 3.8 | · | 3.8 | 3.8 | 4.1 | · | 3.7 | 3.7 | 3.4 | · | 3.5 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.14 | $6.39 | · | $6.50 | $6.64 | $6.92 | · | $7.09 | $7.16 | $7.25 | · | $7.44 | $7.52 | $7.66 | · | $8.00 | |
| Revenue / Share | $1.54 | $1.45 | · | $1.46 | $1.42 | $1.32 | · | $1.32 | $1.30 | $1.24 | · | $1.21 | $1.17 | $1.10 | · | $1.03 | |
| Cash Flow / Share | · | $-0.06 | · | · | · | $-0.20 | · | · | · | $-0.21 | · | · | · | $-0.10 | · | · | |
| Cash / Share | $1.14 | $1.13 | · | $1.27 | $1.20 | $2.70 | · | $2.83 | $2.78 | $2.60 | · | $2.41 | $2.27 | $2.17 | · | $2.10 | |
| EPS (TTM) | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $766M | $746M | · | $709M | $689M | $672M | · | $644M | $628M | $611M | · | $575M | $552M | $530M | · | $497M | |
| Net Income TTM | $-52M | $-99M | · | $-113M | $-104M | $-78M | · | $-78M | $-79M | $-84M | · | $-96M | $-115M | $-126M | · | $-163M | |
| Market Cap | $1.87B | $962M | · | $995M | $941M | $1.22B | · | $1.89B | $1.77B | $2.00B | · | $1.57B | $2.04B | $2.21B | · | $1.09B | |
| Enterprise Value | $2.10B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -60.8 | -30.9 | · | -32.2 | -30.5 | -39.5 | · | -61.5 | -57.8 | -65.5 | · | -51.2 | -67.0 | -72.5 | · | -35.9 | |
| P/S | 2.4 | 1.3 | · | 1.4 | 1.4 | 1.8 | · | 2.9 | 2.8 | 3.3 | · | 2.7 | 3.7 | 4.2 | · | 2.2 | |
| P/B | 2.4 | 1.2 | · | 1.2 | 1.1 | 1.4 | · | 2.1 | 1.9 | 2.2 | · | 1.7 | 2.1 | 2.3 | · | 1.1 | |
| P / Tangible Book | · | 37.2 | · | 50.3 | 33.5 | 35.6 | · | 50.5 | 48.3 | 55.8 | · | 36.6 | 47.8 | 42.4 | · | 14.9 | |
| P / Cash Flow | · | -118.2 | · | · | · | -48.1 | · | · | · | -77.3 | · | · | · | -174.5 | · | · | |
| EV / Revenue | 2.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -1.6% | -3.2% | · | -3.1% | -3.3% | -2.5% | · | -1.6% | -1.7% | -1.5% | · | -1.9% | -1.5% | -1.4% | · | -2.8% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $727M | $661M | $592M | $510M | $484M |
| Brüt Kâr Marjı % | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% |
| Faaliyet Kâr Marjı % | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% |
| Net Gelir | $-108M | $-79M | $-88M | $-144M | $-8M |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.4 | 0.6 | · | · | · |
| Cari Oran | 4.3 | 2.0 | 6.2 | 6.7 | 7.8 |
| Cari Oran | 3.6 | 1.7 | 4.9 | 4.3 | 4.9 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-22M | $-34M | $-31M | $-97M | $-91M |
Kurumsal Sahipler (13F) 296 dosya · $2.4B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
296
Tutulan Değer
$2.4B
Yeni pozisyonlar
58
Çıkan pozisyonlar
38
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 58 (+9 önceki Ç'ye göre) | 38 (+2 önceki Ç'ye göre) | 100 (+22 önceki Ç'ye göre) | 61 (-22 önceki Ç'ye göre) | +19.6M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $304.469.400 | 20.868.362 | 12,94% | Hisse senetleri |
| First Light Asset Management, LLC | $179.158.241 | 12.279.523 | 7,61% | Hisse senetleri |
| VANGUARD GROUP INC | $162.621.455 | 13.828.355 | 6,91% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $147.552.477 | 10.113.261 | 6,27% | Hisse senetleri |
| Greenhouse Funds LLLP | $125.097.724 | 8.574.210 | 5,32% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $117.615.272 | 8.061.362 | 5,00% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $84.082.418 | 5.763.017 | 3,57% | Hisse senetleri |
| STATE STREET CORP | $78.257.609 | 5.363.784 | 3,33% | Hisse senetleri |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $73.501.000 | 5.037.787 | 3,12% | Hisse senetleri |
| BRAIDWELL LP | $71.756.567 | 4.918.202 | 3,05% | Hisse senetleri |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $61.886.083 | 4.342.883 | 2,63% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $50.558.727 | 3.465.300 | 2,15% | Alım opsiyonu |
| GEODE CAPITAL MANAGEMENT, LLC | $50.025.999 | 3.428.123 | 2,13% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $44.930.518 | 3.079.542 | 1,91% | Hisse senetleri |
| TORONTO DOMINION BANK | $43.770.000 | 3.000.000 | 1,86% | Alım opsiyonu |
| LOOMIS SAYLES & CO L P | $37.025.291 | 2.537.717 | 1,57% | Hisse senetleri |
| Driehaus Capital Management LLC | $36.604.049 | 2.508.845 | 1,56% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $35.546.038 | 2.436.329 | 1,51% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $35.003.708 | 2.399.411 | 1,49% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $34.896.129 | 2.391.784 | 1,48% | Hisse senetleri |
| AMERICAN CAPITAL MANAGEMENT INC | $32.648.145 | 2.237.707 | 1,39% | Hisse senetleri |
| UBS Group AG | $32.581.659 | 2.233.150 | 1,38% | Alım opsiyonu |
| D. E. Shaw & Co., Inc. | $32.021.519 | 2.194.758 | 1,36% | Hisse senetleri |
| SAMLYN CAPITAL, LLC | $31.096.207 | 2.131.337 | 1,32% | Hisse senetleri |
| Aberdeen Group plc | $28.180.950 | 1.931.525 | 1,20% | Hisse senetleri |
| MORGAN STANLEY | $27.693.709 | 1.898.128 | 1,18% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $22.859.028 | 1.566.760 | 0,97% | Hisse senetleri |
| NORTHERN TRUST CORP | $22.456.651 | 1.539.181 | 0,95% | Hisse senetleri |
| GLENMEDE TRUST CO NA | $22.141.579 | 1.517.586 | 0,94% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17.689.018 | 1.212.407 | 0,75% | Hisse senetleri |
| SEGALL BRYANT & HAMILL, LLC | $15.850.518 | 1.086.396 | 0,67% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $12.685.640 | 869.475 | 0,54% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $12.149.312 | 832.715 | 0,52% | Hisse senetleri |
| Glenmede Investment Management, LP | $12.057.018 | 1.561.790 | 0,51% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $11.709.890 | 802.597 | 0,50% | Hisse senetleri |
| Bank of New York Mellon Corp | $10.743.609 | 736.368 | 0,46% | Hisse senetleri |
| CITIGROUP INC | $9.748.716 | 668.178 | 0,41% | Hisse senetleri |
| PRINCIPAL FINANCIAL GROUP INC | $9.189.162 | 629.826 | 0,39% | Hisse senetleri |
| HighMark Wealth Management LLC | $8.936.871 | 612.534 | 0,38% | Hisse senetleri |
| Invesco Ltd. | $8.754.555 | 600.038 | 0,37% | Hisse senetleri |
| UBS Group AG | $8.391.672 | 575.166 | 0,36% | Hisse senetleri |
| JPMORGAN CHASE & CO | $8.363.938 | 581.091 | 0,36% | Hisse senetleri |
| JUPITER ASSET MANAGEMENT LTD | $7.841.935 | 537.487 | 0,33% | Hisse senetleri |
| Public Sector Pension Investment Board | $6.526.545 | 447.330 | 0,28% | Hisse senetleri |
| Trexquant Investment LP | $6.358.074 | 435.783 | 0,27% | Hisse senetleri |
| Nuveen, LLC | $6.172.300 | 423.050 | 0,26% | Hisse senetleri |
| Granite Investment Partners, LLC | $5.181.507 | 355.141 | 0,22% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $4.625.865 | 317.057 | 0,20% | Hisse senetleri |
| RHUMBLINE ADVISERS | $4.624.054 | 316.935 | 0,20% | Hisse senetleri |
| Legal & General Group Plc | $4.317.503 | 295.922 | 0,18% | Hisse senetleri |
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| IRS IDENTIFICATION NO. NeoGenomics, Inc. | 12 Nisan 2007 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 52 içeriden öğrenenler · 31 yöneticiler · 23 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Anthony P. Zook | Chief Executive Officer | 01 Nisan 2026 M | 133.111 | 0 | 0 | $0 |
| Christopher M Smith | Chief Executive Officer | 23 Şubat 2025 M | 641.585 | 0 | 0 | $0 |
| Mark Mallon | Chief Executive Officer | 01 Mart 2022 A | 368.051 | 0 | 0 | $0 |
| Jeffrey Scott Sherman | Chief Financial Officer | 23 Şubat 2026 M | 220.009 | 0 | 0 | $0 |
| William Bonello | Chief Financial Officer | 28 Nisan 2022 M | 191.548 | 0 | 0 | $0 |
| Sharon Virag | Chief Financial Officer | 01 Mart 2019 A | 10.944 | 0 | 0 | $0 |
| Vishal Sikri | President Advanced Diagnostics | 23 Şubat 2024 A | 127.716 | 0 | 0 | $0 |
| David Sholehvar | President, Clinical Services | 01 Ağustos 2022 A | 43.216 | 0 | 0 | $0 |
| George Cardoza | President & COO, Lab Ops | 02 Mart 2022 F | 244.157 | 0 | 0 | $0 |
| Gina M Wallar | President, Pharma Services | 01 Mart 2022 A | 33.443 | 0 | 0 | $0 |
| Clive Morris | President of Inivata | 30 Aralık 2021 A | 41.280 | 0 | 0 | $0 |
| Robert J. Shovlin | President, Clinical Services | 25 Mayıs 2021 M | 150.101 | 0 | 0 | $0 |
| Warren Stone | Pres & Chief Operating Officer | 21 Ağustos 2026 M | 181.078 | 0 | 1 | $-276.600 |
| Alicia C Olivo | EVP, GC & Business Development | 01 Eylül 2026 F | 90.875 | 0 | 2 | $-300.172 |
| Greg D Aunan | Chief Accounting Officer | 04 Ağustos 2026 S | 5.153 | 0 | 1 | $-321.400 |
| Melody Harris | Chf Ops Off, Pres, Informatics | 23 Şubat 2025 M | 109.755 | 0 | 0 | $0 |
| Shashikant Kulkarni | Chief Scientific Officer | 01 Nisan 2023 F | 82.673 | 0 | 0 | $0 |
| Cynthia J Dieter | Chief Accounting Officer | 02 Mart 2023 F | 29.765 | 0 | 0 | $0 |
| Douglas Matthew Brown | Chief Strategy Officer | 01 Nisan 2022 A | 158.684 | 0 | 0 | $0 |
| Halley E Gilbert | Chief Legal Officer | 01 Mart 2022 A | 147.396 | 0 | 0 | $0 |
| Kathryn B Mckenzie | Chief Sustainability/Risk Ofcr | 11 Ocak 2022 M | 49.361 | 0 | 0 | $0 |
| Jennifer Balliet | VP and Chief Culture Officer | 30 Aralık 2021 A | 48.615 | 0 | 0 | $0 |
| Lawrence Martin Weiss | Chief Medical Officer | 22 Nisan 2021 M | 130.847 | 0 | 0 | $0 |
| Denise E Pedulla | General Counsel | 02 Mart 2021 A | 60.643 | 0 | 0 | $0 |
| Steven G. Brodie | VP - Pharma Operations | 22 Ekim 2018 M | 45.953 | 0 | 0 | $0 |
| Steven A Ross | CIO | 10 Mayıs 2018 X | 4.500 | 0 | 0 | $0 |
| Maher Albitar | Chief Medical Officer | 25 Mayıs 2017 A | 60.692 | 0 | 0 | $0 |
| Mark Alan Machulcz | Vice President of Operations | 28 Ocak 2016 A | · | 0 | 0 | $0 |
| Robert H. Horel | Vice President GM PathLogic | 29 Aralık 2015 X | 51.218 | 0 | 0 | $0 |
| Robert P Gasparini | Chief Science Officer | 22 Mayıs 2014 X | 8.439 | 0 | 0 | $0 |
| Mark W Smits | Chief Commercial Officer | 18 Mayıs 2011 M | 0 | 0 | 0 | $0 |
| Carolyn S Starrett | Yönetim kurulu üyesi | 23 Haziran 2026 A | · | 0 | 0 | $0 |
| Lynn A. Tetrault | Yönetim kurulu üyesi | 15 Haziran 2026 S | 86.115 | 0 | 2 | $-118.824 |
| Marjorie C Green | Yönetim kurulu üyesi | 01 Haziran 2026 A | 22.964 | 0 | 0 | $0 |
| Neil Gunn | Yönetim kurulu üyesi | 01 Haziran 2026 A | 51.177 | 0 | 0 | $0 |
| Michael Aaron Kelly | Yönetim kurulu üyesi | 01 Haziran 2026 A | 67.086 | 0 | 0 | $0 |
| David Brian Perez | Yönetim kurulu üyesi | 01 Haziran 2026 A | 56.967 | 0 | 0 | $0 |
| John P. Kenny | Yönetim kurulu üyesi | 01 Haziran 2026 A | 5.893 | 0 | 0 | $0 |
| Stephen M Kanovsky | Yönetim kurulu üyesi | 01 Haziran 2026 A | 75.421 | 0 | 0 | $0 |
| Felicia Williams | Yönetim kurulu üyesi | 01 Haziran 2026 A | 30.237 | 0 | 0 | $0 |
| Elizabeth Floegel | Yönetim kurulu üyesi | 01 Haziran 2025 A | 23.590 | 0 | 0 | $0 |
| Alison L. Hannah | Yönetim kurulu üyesi | 01 Haziran 2025 M | 131.023 | 0 | 0 | $0 |
| Bruce K Crowther | Yönetim kurulu üyesi | 10 Ağustos 2023 A | 65.120 | 0 | 0 | $0 |
| Rachel A Stahler | Yönetim kurulu üyesi | 10 Haziran 2022 A | 21.335 | 0 | 0 | $0 |
| David Daly | Yönetim kurulu üyesi | 10 Haziran 2022 A | 17.179 | 0 | 0 | $0 |
| Kevin C Johnson | Yönetim kurulu üyesi | 22 Aralık 2021 M | 37.398 | 0 | 0 | $0 |
| Douglas M Van Oort | Yönetim kurulu üyesi | 01 Ağustos 2021 F | 2.468.797 | 0 | 0 | $0 |
| Steven C Jones | Yönetim kurulu üyesi | 07 Ocak 2021 M | 90.218 | 0 | 0 | $0 |
| Raymond R Hipp | Yönetim kurulu üyesi | 16 Kasım 2020 S | 66.800 | 0 | 0 | $0 |
| William J Robison | Yönetim kurulu üyesi | 25 Mayıs 2017 A | 183.348 | 0 | 0 | $0 |
| Michael T Dent | Yönetim kurulu üyesi | 04 Aralık 2014 S | 1.384.150 | 0 | 0 | $0 |
| Peter M Peterson | Yönetim kurulu üyesi | 05 Haziran 2012 A | 34.500 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 52 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| PTH · Invesco Exchange-Traded Fund Trust | 1,36% | 220.212 SH | 02 Ekim 2026 | Günlük |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,25% | 122.042 SH | 02 Ekim 2026 | Günlük |
| XSMO · Invesco Exchange-Traded Fund Trust | 0,81% | 1.312.429 SH | 02 Ekim 2026 | Günlük |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,71% | 601.468 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,38% | 86.758 SH | 02 Ekim 2026 | Günlük |
| IHF · iShares Trust | 0,34% | 250.331 SH | 11 Eylül 2026 | Günlük |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,27% | 239.159 NS | 31 Temmuz 2026 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,15% | 19.929 SH | 02 Ekim 2026 | Günlük |
| NUSC · Nushares ETF Trust | 0,15% | 126.293 NS | 31 Temmuz 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,14% | 54.487 NS | 31 Temmuz 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,12% | 89.895 SH | 19 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,12% | 176.579 SH | 02 Ekim 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,11% | 104.297 SH | 19 Ağustos 2026 | Günlük |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,10% | 455.144 SH | 19 Ağustos 2026 | Günlük |
| ESML · iShares Trust | 0,09% | 146.435 SH | 11 Eylül 2026 | Günlük |
| VIOV · VANGUARD ADMIRAL FUNDS | 0,09% | 116.046 SH | 19 Ağustos 2026 | Günlük |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0,09% | 33.444 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 3.367.792 SH | 11 Eylül 2026 | Günlük |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 34.215 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,07% | 40.558 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,06% | 63.019 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,06% | 757.699 SH | 19 Ağustos 2026 | Günlük |
| SMDX · Tidal Trust III | 0,05% | 4.493 NS | 31 Temmuz 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,05% | 1.728.845 SH | 19 Ağustos 2026 | Günlük |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 55.092 SH | 02 Ekim 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,04% | 358.850 NS | 31 Temmuz 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,03% | 388.986 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,03% | 10.624 SH | 11 Eylül 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 62.331 NS | 31 Temmuz 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,02% | 8.379 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 1.492.431 SH | 19 Ağustos 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.990.594 SH | 19 Ağustos 2026 | Günlük |
| IWO · iShares Trust | 0,01% | 115.979 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,01% | 344.253 NS | 31 Temmuz 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,01% | 15.340 NS | 31 Temmuz 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 12.627 SH | 19 Ağustos 2026 | Günlük |
| DCOR · Dimensional ETF Trust | 0,01% | 14.534 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 30.125 NS | 31 Temmuz 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 47.070 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 172.474 SH | 11 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 4.536 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35.356 SH | 10 Eylül 2026 | Günlük |
| IXUS · iShares Trust | 0,00% | 56.854 SH | 11 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.136.535 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10.236 SH | 19 Ağustos 2026 | Günlük |
| IJR · iShares Trust | · | 7.951.677 SH | 10 Eylül 2026 | Günlük |
| IJT · iShares Trust | · | 716.232 SH | 09 Eylül 2026 | Günlük |
| IJS · iShares Trust | · | 490.259 SH | 08 Eylül 2026 | Günlük |
| IWN · iShares Trust | · | 1.129.992 SH | 11 Eylül 2026 | Günlük |
| XJR · iShares Trust | · | 18.003 SH | 31 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 5.811 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 45.624 SH | 11 Eylül 2026 | Günlük |
NEO Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 16 analist
AL
Medyan hedef
$19.00
+2,9%
4 25,0%
Güçlü Al
7 43,8%
Al
5 31,2%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
9 analist · 2026-10-02Ortalama hedef $19.72 +6,8%
Şimdi
Mevcut fiyat $18.47
Düşük$16.00
Ortalama$19.72
Yüksek$35.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| NEO | $1.51B | -49.0 | 10.1% | -14.8% | -12.8% | 43.2% |
| OPCH | $5.00B | 25.1 | 13.0% | 3.7% | 15.4% | 19.3% |
| AVAH | $1.70B | 7.7 | 20.2% | 9.2% | 246.6% | 33.3% |
| GRDN | · | · | 17.9% | 3.4% | 24.8% | 20.2% |
| PRVA | $2.93B | 131.7 | 22.3% | 1.1% | 3.3% | · |
| MD | $1.77B | 11.0 | -4.9% | 8.6% | 20.3% | · |
| ADUS | · | 20.6 | 23.2% | · | · | · |
| WGS | · | · | · | · | · | · |
| ASTH | $1.21B | 53.9 | 56.4% | 0.71% | 3.0% | · |
| AMN | $606M | -6.4 | -8.5% | -3.5% | -15.3% | 28.3% |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Tem 28, 2026